Alexis Santangelo, NP
Gerontology · San Antonio, TXNPI 1881078624
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.6%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by AbbVie at 54.7% of the total. Reporting peaked in 2022 at $3,555 and has fallen 72.9% since, to $965 in 2025. Among gerontology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 104 payments — averaging $87.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Amneal Pharmaceuticals LLC$2K
- MDD US Operations, LLC$500
- Kyowa Kirin, Inc.$483
- Neurocrine Biosciences, Inc.$374
- Medtronic$233
- plus $905 from 12 others
Across 1 payment — averaging $280.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$280
What the payments were for
- Consulting fees$1,75219%
- Speaking & faculty fees$4,60051%
- Travel & lodging$400%
- Food & beverage$2,59129%
- Education$1011%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 21 | $4,972 |
| Amneal Pharmaceuticals LLC | 15 | $1,618 |
| MDD US Operations, LLC | 2 | $500 |
| Kyowa Kirin, Inc. | 7 | $483 |
| Neurocrine Biosciences, Inc. | 20 | $374 |
| Medtronic | 4 | $233 |
| Teva Pharmaceuticals USA, Inc. | 9 | $215 |
| Sunovion Pharmaceuticals Inc. | 10 | $180 |
| Merz Pharmaceuticals, LLC | 1 | $125 |
| Acadia Pharmaceuticals Inc | 5 | $121 |
| Abbott | 1 | $121 |
| Acorda Therapeutics, Inc | 3 | $46 |
| Avanir Pharmaceuticals, Inc. | 1 | $21 |
| Upsher-smith Laboratories LLC | 1 | $17 |
| Boston Scientific | 1 | $17 |
| Cala Health, Inc. | 1 | $15 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
| Avion Pharmaceuticals | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,085 in reported general payments places this provider in the 95th percentile of 653 gerontology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 32 | $354,440 |
| RytaryCarbidopa/Levodopa | 178 | $314,429 |
| Austedo XrDeutetrabenazine | 23 | $282,808 |
| IngrezzaValbenazine Tosylate | 13 | $170,018 |
| InbrijaLevodopa | 14 | $44,471 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 548 | $21,065 |
| NeuproRotigotine | 15 | $15,328 |
| Entacapone | 66 | $12,835 |
| CrexontCarbidopa/Levodopa | 18 | $10,034 |
| Rasagiline Mesylate | 53 | $9,381 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 265 | $8,019 |
| AmantadineAmantadine Hcl | 125 | $6,352 |
| Droxidopa | 13 | $5,544 |
| RivastigmineRivastigmine Tartrate | 38 | $4,992 |
| Tetrabenazine | 11 | $4,609 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $215 | $637,24855 claims |
| Amneal Pharmaceuticals LLCRytary, Crexont | $1,618 | $324,463196 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $374 | $170,01813 claims |
| Acorda Therapeutics, IncInbrija | $46 | $44,47114 claims |
| Upsher-smith Laboratories LLCTopiramate | $17 | $36516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 653 gerontology providers in Texas.
Other gerontology in San Antonio
- Cecilia OrtizSan Antonio$13K
- Bianca LopezSan Antonio$11K
- Juliet GatobuSan Antonio$7K
- Ashlee DuggerSan Antonio$7K
- Amy RomickSan Antonio$5K
- Diana GarzaSan Antonio$4K
- Kimberly WelchCoppell$113K
- Tiffany KesslerDallas$84K
- Jennifer WestFort Worth$67K
- Bailey EstesAbilene$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.